New Frontiers in the Treatment and Management of Relapsed/Refractory Multiple Myeloma: A Closer Look at the Role of Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme

Description:
Multiple myeloma (MM) is a systemic malignancy of plasma cells that is highly treatable but rarely curable. The median survival in the prechemotherapy era was about 7 months however new and emerging treatment options are currently undergoing late stage clinical trials and have shown great outcomes and real-world data in their ability to improve clinical and economic outcomes. MM is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as the hemoglobin and serum calcium concentrations, amongst other factors. The stage of the disease at presentation is a strong determinant of survival, but it has little influence on the choice of therapy since almost all patients, except for rare patients with solitary bone tumors or extramedullary plasmacytomas, have generalized disease. Treatment selection is influenced by the age and general health of the patient, prior therapy, and the presence of complications of the disease. Treatment is directed at reducing the tumor cell burden and reversing any complications of disease, such as renal failure, infection, hyperviscosity, or hypercalcemia with appropriate medical management. MM remains a disease with poor long-term survival as it is currently incurable and all patients will eventually relapse, underlining the need for new therapies.

Upon completion of this activity, participants will be able to:

  • Summarize new evidence on the treatment role, efficacy, and safety of novel agent classes and next-generation therapeutics for patients with relapsed or refractory multiple myeloma

  • Examine the role of emerging anti-CD38 monoclonal antibodies in the relapsed/refractory multiple myeloma treatment paradigm

  • Asses the roles of monoclonal antibodies and BCL-2 inhibitors in the management of relapsed/refractory multiple myeloma

  • Describe the advantages and limitations of measuring minimal residual disease (MRD) and differentiate next generation sequencing (NGS) and next-generation flow cytometry (NGF) from earlier-generation tests

  • Discuss managed care considerations of emerging novel therapies by exploring where these potential agents may fit into current relapsed/refractory multiple myeloma management paradigm

  • Analyze strategies for managing treatment-related adverse events in patients with myeloma who are receiving therapy with regimens that contain novel components
     

Faculty: Ravi Vij, MD
Professor of Medicine, Division of Oncology
Section of Bone Marrow Transplantation
Washington University School of Medicine

Disclosure:

Dr. Vij serves on an advisory board for Celgene, Bristol-Myers Squibb, Karyopharm, Sanofi, and Takeda. He has received research/grant support from Celgene, Bristol-Myers Squibb and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue